Sugammadex Sodium

舒更葡糖钠

Report date: 2022/05/19 14:20:27
NMEFirst In Class

Base Information

Drug NameSugammadex Sodium
Drug Alias Namesugammadexum舒格葡糖舒伽马地舒更葡糖布瑞亭 +[10] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionMuscle relaxation antagonists
TargetsNot applicable
Therapy Area/IndicationsNeuromuscular BlockadeBurnsPostoperative Nausea and Vomiting +[22] 
Global Approved IndicationsNeuromuscular Blockade
Approved Indications in ChinaNeuromuscular Blockade
Original Approved Country/TerritoryEU
Original Approved Date2008/07/25
Country/TerritoryUnited StatesNetherlandsRussian Federation +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital of Air Force Medical UniversityRadboud University Medical CenterWake Forest University Health Sciences +[11] 
Inactive CompaniesWest Virginia UniversityFederal Research Institute of Pediatric Hematology Oncology and ImmunologyOrganon Nv +[4] 
Active IndicationsNeuromuscular BlockadeBurnsPostoperative Nausea and Vomiting +[14] 
Inactive IndicationsAnaphylaxisHypersensitivitybeta-Thalassemia +[8] 

Other Information

ATC CodeV03AB35
Related LinksWikipediaDrugBankKEGG